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Abstract
Background: The pathophysiology of HFE-derived Hereditary Hemochromatosis and the function of HFE protein in iron
homeostasis remain uncertain. Also, the role of alternative splicing in HFE gene expression regulation and the possible
function of the corresponding protein isoforms are still unknown. The aim of this study was to gain insights into the
physiological significance of these alternative HFE variants.
Methodology/Principal Findings: Alternatively spliced HFE transcripts in diverse human tissues were identified by RT-PCR,
cloning and sequencing. Total HFE transcripts, as well as two alternative splicing transcripts were quantified using a real-
time PCR methodology. Intracellular localization, trafficking and protein association of GFP-tagged HFE protein variants
were analysed in transiently transfected HepG2 cells by immunoprecipitation and immunofluorescence assays. Alterna-
tively spliced HFE transcripts present both level- and tissue-specificity. Concerning the exon 2 skipping and intron 4
inclusion transcripts, the liver presents the lowest relative level, while duodenum presents one of the highest amounts. The
protein resulting from exon 2 skipping transcript is unable to associate with b2M and TfR1 and reveals an ER retention.
Conversely, the intron 4 inclusion transcript gives rise to a truncated, soluble protein (sHFE) that is mostly secreted by cells
to the medium in association with b2M.
Conclusions/Significance: HFE gene post-transcriptional regulation is clearly affected by a tissue-dependent alternative
splicing mechanism. Among the corresponding proteins, a sHFE isoform stands out, which upon being secreted into the
bloodstream, may act in remote tissues. It could be either an agonist or antagonist of the full length HFE, through hepcidin
expression regulation in the liver or by controlling dietary iron absorption in the duodenum.
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Introduction
Maintaining iron homeostasis is essential, as both iron
deficiency and iron excess are associated with cellular and
organismal dysfunction. Iron homeostasis is dependent of a tight
link between body iron requirements, storage, recycling from
macrophages, and intestinal iron absorption. However, how
this complex mechanism is controlled remains largely to be
understood.
HFE is a major histocompatibility complex (MHC) class I-like
protein that is mutated in Hereditary Hemochromatosis (HH;
OMIM 235200), a common autosomal recessive disorder of iron
metabolism [1]. The disease is characterized by excessive intestinal
iron absorption and iron deposition in organs such as liver, heart
and pancreas, potentially leading to cirrhosis, hepatocellular
carcinoma, diabetes, cardiac failure and arthritis [2]. HFE is a
transmembrane protein formed by six distinct domains: a signal
peptide, three extracellular domains (a1, a2 and a3), a
transmembrane region and a short cytoplasmic tail [1]
(Figure 1A). It assembles with its chaperone beta2-microglobulin
(b2M) to form an heterodimer expressed at the cell surface. The
most common HH-associated HFE mutation, C282Y, abrogates
the disulfide bond in the protein a3 domain and prevents its
binding to b2M and cell surface presentation [3].
HFE protein has been detected in various cell types. It is
expressed throughout the gastrointestinal tract as well as in
macrophages and monocytes [4,5]. In the human liver, HFE was
shown to be present on Kupffer cells and endothelium [6]. In a
variety of transfected cells, HFE co-localizes with transferrin
receptor 1 (TfR1) at the cell surface and in perinuclear
compartments, namely the endosomal compartment [7–9]. At
cell surface, both HFE and diferric-iron-loaded transferrin (Fe2-
Tf) recognize overlapping regions on TfR1, which results in
competition for binding to this receptor [10]. However, HFE is
also able to interact with the liver-specific TfR1 homologue, TfR2
[11]. Recently, it was proposed that, under normal conditions,
HFE is partitioned between TfR1 and TfR2, and an increase in
Fe2-Tf saturation results in stabilization of TfR2 protein and
degradation of TfR1 mRNA [12]. Under these conditions, HFE
should shift away from TfR1 towards TfR2, so TfR2-HFE
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the induction of the iron regulatory hormone hepcidin [13,14].
The HFE gene (formerly known as HLA-H) is located at 6p21.3
and its genomic structure resembles other MHC class I molecules
[1]. It is known that alternative splicing mechanism is a
widespread mean for producing polypeptide diversity from a
single gene [15,16]. Accordingly, alternative splicing is a common
process of producing MHC class I protein isoforms. For instance,
HLA-G, which is a non-typical MHC class I protein that presents
significant structural homology to HFE, shows alternative splicing
expression regulation and some of the isoforms produced have
specific biological functions [17,18]. Previous studies have shown
that HFE gene expression is subjected to alternative splicing as well
[19–22]. The predominant HFE transcript has about 4.2 kb, but
additional transcripts have also been reported, which seem to
differ in both level- and the tissue- or cellular-specificity. However,
the identification of HFE alternative transcripts, their tissue-
specificity and abundance, as well as the biological significance of
the corresponding isoforms, remains to be clarified.
As a consequence of alternative splicing, soluble protein isoforms
can be originated, assuming in some cases, an important regulatory
role in physiological processes. Actually, a splice variant of HFE
mRNA was described [19] and, although not studied at protein level,
it wassuggestedthatthe corresponding solublepeptidemight regulate
cellular iron transport. In addition, an artificial b2M-HFE mono-
chain, trying to mimic a soluble HFE (sHFE), was constructed and it
was observed that it effectively reduces Tf uptake into cells [23].
However, this did not correlate to any changes in TfR1 or ferritin
synthesis, in contrast to the normal HFE-induction. These findings of
an incongruent soluble b2M -HFE monochain activity suggest that
sHFE may act differently. Nevertheless, the existence and the
biological function of a putative sHFE isoform remained elusive.
In this study, we have characterized several HFE splicing
alternative transcripts in a variety of human tissues, their relative
abundance and tissue-specificity. Raising the hypothesis that some
of the corresponding protein variants might have a biological role,
we analysed those resulting from exon 2 skipping and intron 4
inclusion. By studying their intracellular localization, trafficking and
assembly, we gained insights about their physiological significance.
Therefore, we have demonstrated that a sHFE isoform is secreted
into the medium, maintaining its association to the chaperone b2M.
Results
HFE mRNA is alternatively spliced in different human
tissues
Pools of total RNA from eight human tissues (heart, duodenum,
small intestine, liver, spleen, kidney, ovary and testis) and from
Figure 1. Splicing forms of HFE gene in several human tissues. (A) Schematic representation of the HFE immature protein. The distinct
patterns depict HFE protein domains: the signal peptide (signal), the three extracellular domains (a1, a2 and a3), the transmembrane domain (tm)
and the cytoplasmic tail (cyto). (B) Schematic representation of the major HFE transcript. The length of exons is presented in base pairs (bp). (C) A RT-
PCR using total RNA from eight tissues and HepG2 cell line was performed using primers #1 and #2 (their relative position is indicated with arrows)
and results are shown on the right. The products obtained for each tissue were cloned into the pCRH-TOPO-XLH vector and sequenced. On the left
are schematic representations of the alternative splicing forms identified as well as their length in bp. The asterisks (*) identify bands corresponding
to PCR artefacts as a result from DNA hybrid chains.
doi:10.1371/journal.pone.0017542.g001
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using a specific primer pair (Table 1, primers #1 and #2) in which
primer #2 includes the native HFE’ stop codon in the 59 part of
HFE exon 6, allowed the amplification of the previously predicted
coding region of HFE gene (full length) and theoretically of all the
alternative transcripts resulting from partial or total exon skipping
or intron inclusion that present the native stop. At least eight bands
could be observed in some lanes of the representative gel
photograph (Figure 1B and 1C). To identify the corresponding
HFE transcripts, the RT-PCR products from all samples were
cloned and sequenced. As expected, we found the correctly spliced
full length transcript represented by the 1081 base pair (bp)
fragment. Additionally, we identified two transcripts resulting from
the skipping of a single exon: one corresponds to the HFE exon 2
skipping (817 bp fragment) and the other to the exon 3 skipping
(805 bp fragment). Three other transcripts were also found as a
result of multiple exon skipping: exon 2–3 (541 bp fragment), exon
2–4 (265 bp fragment) and exon 2–5 (151 bp fragment).
Moreover, three other bands (indicated with an asterisk) could
be seen in most of the lanes of the gel (Figure 1C). However, they
were proved, by direct sequencing, to be artefact fragments of
DNA hybrid chains formed during PCR assays.
The full length as well as most of the alternatively spliced HFE
transcripts were found in all the analysed tissues (Figure 1C). As
exon 2 and exon 3 skipping transcripts were not distinguished in
the gel due to their similar molecular weight, their presences in all
tissues were confirmed by additional RT-PCRs (Figure S1, Table
S1). Only the exon 2–5 skipping seems to be tissue-specific, since it
is only present in the gonads, small intestine, duodenum and heart
(Figure 1C). Most of the alternative transcripts were also found in
HepG2 cells, with the exception of the exon 2–4 and exon 2–5
skipping transcripts.
In all of these alternative transcripts, exons are totally skipped
without generating frameshifts. However, in some of them, a single
amino acid change occurs in the new exon-exon junction. As an
example, the alternative transcript with a complete deletion of
exon 2 results in a 260-aa protein variant where the arginine 26
changes to glutamine.
In order to improve the screening for alternatively spliced HFE
transcripts, we performed a search for one previously described,
resulting from the inclusion of intron 4 [19]. So, a specific RT-
PCR using primers located at exons 4 and 5 was performed in all
tissues and HepG2 cells (Figure 2). The amplified products were
cloned and sequenced. Besides the normally spliced, two
additional HFE transcripts were identified, one resulting from
the total intron 4 inclusion (438 bp fragment) and other, not
previously published, resulting from the first 66 bp intron 4
inclusion (346 bp fragment) (Figure 2). These alternative tran-
scripts were observed in all analysed tissues as well in HepG2 cells.
On the other hand, an additional band was presented in the gel
(indicated with an asterisk) that was once again proved by direct
sequencing to be a PCR artefact. The same RT-PCR approach
was replicated using minus RT controls for all the tissues. Result
allows to discard any DNA contamination (Figure S2).
A RT-PCR encompassing exon 1- intron 4 was also performed
in all tissues to confirm the correct splicing of their upstream
coding region (data not shown). So, potentially both transcripts
encode the same and putatively soluble HFE peptide since it
would not have the transmembrane domain (encoded by exon 5)
and the cytoplasmatic tail (encoded by exon 6). Therefore, after a3
domain it would have two extra C-terminal amino acids, glycine
and methionine, encoded by the 59 sequence of intron 4.
Absolute and relative quantification of HFE exon 2
skipping and intron 4 inclusion transcripts reveal a tissue-
specific pattern
In order to further characterize two of the identified alternative
spliced transcripts, resulting from exon 2 skipping or intron 4
insertion, absolute quantification of the total HFE mRNA along
with these mentioned transcripts was performed by quantitative
real-time PCR (qRT-PCR). These two species were chosen
because of the clear opposite outcome that, hypothetically, they
could have. The exon 2 skipping corresponding protein will miss
the a1 domain, which is essential for the interaction with TfR1. In
contrast, the intron 4 insertion corresponding protein will have the
three a domains required for interaction with TfR1 and b2M but
will not contain the transmembrane region and the cytoplasmic
tail.
The approach used was an accurate two-step real-time RT-
PCR described for appropriate measurement of several low-
abundance mRNA splice variants [24]. Four independent reverse
transcription assays were performed, using total RNA from each
tissue, which allowed to conclude about inter-assay variation.
Since HFE exon 6 is present in the full length as well as in all the
abnormally spliced transcripts, primers located in this exon were
used to quantify the total HFE transcripts. For the same reason, in
order to corroborate this quantification data, a similar procedure
was made using primers located in exon 1 (data not shown).
Specific primer sets were designed based on differences in the
splicing pattern of each alternative transcript, where the sequence
is unique. For instance, to quantify the exon 2 skipping transcript,
a specific primer was designed spanning the exon 1/3 boundary,
whereas to quantify the intron 4 inclusion a primer spanning
intron 4/exon 5 boundary was used. An absolute quantification
method was performed using serial dilutions of plasmid constructs
as standards (8610
5 – 80 copies), previously obtained by cloning
the RT-PCR fragments into the pCRH-TOPO-XL vector. Each
reaction was done in triplicate. Linear regression analysis of each
standard curve from all plates was used to quantify transcript
levels. The correlation coefficients ranged from 0.986 to 0.999,
indicating low intra-assay variation. Quantification of total and
Table 1. DNA oligonucleotides used in the current work.
Primer Localization Sequence (59R39)
#1 Exon 1 ATGGGCCCGCGAGCCAGGCCG
#2 Exon 6 GTCTCCTTCCCACAGTGAGTCTGCAGGCTG
#3 Exon 4 GAACATCACCATGAAGTGGCTGAAGG
#4 Exon 5 GAACAAAATTCCAATGAACAAGATGACG
#5 Exon 6 CTACGTCTTAGCTGAACGTGAGTGA
#6 Exon 6 TGTCTCCTTCCCACAGTGAGTCT
#7 Exon 1/3 TGCAGGGTGTGGGACTGCAGCAAGCG
#8 Intron 4 GGCAATCAAAGGCTTTAACTTGCTTTT
#9 Intron 4/Exon 5 CCAGACGGTGAGGGCTCTAA
#10 Exon 1 TTTTGGTACCATGGGCCCGCGAGCC
#11 Exon 6 TTTTGGATCCCACTCACGTTCAGCTAAGA-
CGTAGTGCCC
#12 Exon 4 GGGAAGAGCAGAGATATACGTACCAGGT-
GGAGCACCC
#13 Exon 4 GGGTGCTCCACCTGGTACGTATATCTCTG-
CTCTTCCC
#14 Intron 4 TTTTGGATCCCACATACCCCAGATCACAA-
TGAGG
doi:10.1371/journal.pone.0017542.t001
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and all standard deviations were less than 0.38 Ct.
The qRT-PCR methodology performed allowed the quantifi-
cation of total HFE as well as the two alternative HFE transcripts
in all analysed tissues (Figure 3). The standard deviations
presented in these experiments reflect similar RT efficiency,
which indicates low inter-assay variation. Absolute quantification
(presented as HFE copy number/mg RNA) showed that ovary and
liver have the highest level of total HFE mRNA while, on the
contrary, the smallest amount is present in duodenum (Figure 3).
Comparing the two tissues thought to be targets for HFE function,
liver presents an amount of total HFE mRNA approximately 4.3-
fold higher than duodenum.
Similarly, the relative quantification of the exon 2 skipping and
intron 4 inclusion transcripts also revealed a differential expression
in the analysed tissues. For instance, the liver presents the lowest
relative amount of both transcripts (3 and 6%, respectively) and,
on the contrary, testis (26 and 35%, respectively) and the
duodenum (20 and 25%, respectively) are the tissues where they
are more expressed (Figure 3).
HFE variants present distinct subcellular localization
In an attempt to characterize the cellular localization of the
corresponding HFE protein splice variants, HFE cDNAs (corre-
sponding to the full length HFE mRNA, exon 2 skipping and
intron 4 inclusion transcripts) were tagged to the GFP gene in the
pEGFP-N1 vector (Clontech). In addition, a construct containing
the full length HFE C282Y mutant was made to be used as a
dysfunctional control.
Since we previously have shown that HepG2 cells endogenously
express the HFE exon 2 skipping and intron 4 inclusion
transcripts, they provide a suitable model to further characterize
the corresponding transgenic proteins. This artificial system was
developed due to the lack of suitable anti-HFE antibodies available
for endogenous protein detection. Therefore, these cells were
transiently transfected with the mentioned constructs. Confocal
microscopy analysis of the subcellular localization of (i) the full
length HFE protein, (ii) proteins related to the two splice
transcripts, and (iii) the mutated HFE_C282Y was performed
using antibodies against b2M, calnexin (an endoplasmic reticulum,
ER, marker) and TfR1 (Figure 4). Nuclei were stained with DAPI.
Under these conditions, HFE_full length protein presents mostly a
perinuclear and cell membrane distribution. As expected, it co-
localizes with b2M and TfR1 proteins. On the contrary, also as
expected, HFE_C282Y is not present at the cell surface and has a
diffuse cytoplasmic localization. It seems not to co-localize with
b2M and TfR1, being retained in the ER, as revealed by the
calnexin co-localization (Figure 4). As well, the intracellular
distribution of HFE_skip2 variant is similar to the one obtained
for the HFE_C282Y variant, since it appears to be co-localized
with calnexin but not with b2M and TfR1. Concerning the
HFE_ivs4 variant, it presents a scattered intracellular distribution
and is apparently absent from the cell membrane. It seems not to
co-localize with either b2M or TfR1 and to be present in the ER
(Figure 4). Since the fluorescence microscopy data only hints about
the localization of these variants, immunoprecipitation assays were
performed to all the HFE variants to further clarify these results.
Immunoprecipitation assays reveal a soluble and
secreted HFE protein isoform
To confirm our protein co-localization data observed in
immunofluorescence assays, proteins obtained from cell lysates
as well as from cell culture supernatants were subjected to
immunoprecipitation assays using a mouse anti-GFP antibody
(Figure 5). In cell lysate experiments, the HFE_full length protein
is bound to b2M and TfR1, while HFE_C282Y does not co-
immunoprecipitate with these proteins. Similarly, HFE_skip2
variant does not bind to either b2M or TfR1. In addition, it can
be observed that HFE_ivs4 variant seems to be present at low level
in cell lysates (of different type of cells) in association with b2M but
not with TfR1 (Figure 5A and B) These results are in agreement
with those obtained by immunofluorescence experiments
(Figure 4). The same procedures carried out in the corresponding
cell culture supernatants reveal that HFE_full length,
HFE_C282Y and HFE_skip2 are absent from the culture media
(Figure 5C). Conversely and interestingly, the HFE_ivs4 variant is
clearly shown in the culture supernatant in association with its
chaperone b2M. In order to ascertain that the presence of the
Figure 2. Expression of the intron 4 inclusion HFE splice transcript in several human tissues. A specific RT-PCR to amplify the region
between HFE exon 4 to 5 using total RNA from eight tissues and HepG2 cells was performed. These amplified products were cloned into the pCRH-
TOPO-XLH vector for automated sequencing and further identification. A schematic representation of the HFE gene exon 4 to 5 is presented on the
left. The intron 4 (IVS4) contains a stop codon (TGA) six nucleotides from the exon 4 boundary. The position of the primers (#3 and #4) used in the
PCR and schematic representations of the identified alternative splicing forms are revealed. Correspondence between these splicing forms and the
PCR amplification products is shown, along with their length in bp. The asterisks (*) identify bands corresponding to PCR artefacts as a result from
DNA hybrid chains.
doi:10.1371/journal.pone.0017542.g002
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basic result of cell leakage, a secretion inhibitor was used (Exo 1).
The results presented in Figure 6 shows that when we inhibited
secretion we almost not detect sHFE-GFP in the extracellular
supernatant, even though the protein is detected intracellularly.
Furthermore, the secretion of sHFE-GFP was also confirmed to
occur in other types of transfected cell lines: HuH7, HEK293,
HeLa and CaCo2 (the latter results are shown in Figure S3). In all
cases, this isoform is largely secreted to cell medium remaining
linked to the b2M, as shown by immunoprecipitation experiments.
This result reveals for the first time a soluble form of HFE-GFP
protein (sHFE- GFP) which is secreted to the cell medium, as it
lacked the transmembrane and cytoplasmic domains.
Discussion
Alternative mRNA splicing is a complex post-transcriptional
mechanism that enables the generationof multiple mRNA products
from a single gene, increasing transcriptome and proteome
complexity. So, by this way, a single gene can produce proteins
with different properties and functions, which might differ in a
tissue- ordevelopmentalstage-specific manner.Herewereportthat,
in addition to full length HFE, at least seven alternatively spliced
HFE transcripts are expressed in several human tissues, differing in
the level- and the tissue-specificity. Some studies had already shown
that HFE gene is subjected to alternative splicing processes [19–22].
However, the precise characterization of the alternative transcripts,
their tissue-specificity and abundance, as well as the intracellular
localization and biological significance of the corresponding protein
isoforms remain largely to be clarified.
The search and identification of HFE transcripts in a range of
human tissues (heart, duodenum, small intestine, liver, spleen,
kidney, ovary and testis) allowed us to distinguish, besides the full
length, seven alternative splicing transcripts. Among them, the one
resulting from the first 66 bp intron 4 inclusion was not previously
published. Some other HFE transcripts have been previously
described but were not found in this analysis, e.g. an in-frame
deletion of the first 69 bp of exon 2 was identified in HepG2 cells
by Sanchez et al. [22]. Nevertheless, this transcript was also not
found in studies performed by other authors in several cell lines
and in peripheral blood lymphocytes [20,21].
In this work, two transcripts were chosen to be further
characterized as they have the potential to produce opposite
structural protein outcomes, those resulting from the exon 2
skipping and intron 4 inclusion. So, an absolute and a relative
quantification of total HFE transcripts as well as of the two
Figure 3. Absolute and relative quantification of the exon 2 skipping and intron 4 inclusion HFE splice transcripts. Absolute
quantification of total HFE and of two alternative splicing transcripts was performed by the absolute quantification method using serial dilutions of
plasmids as standards. The histogram shows the mean and standard deviations from four independent experiments. The relative levels of the
alternatively spliced transcripts resulting from exon 2 skipping and intron 4 inclusion are shown as a percentage of the total HFE (defined as 100%).
doi:10.1371/journal.pone.0017542.g003
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samples of RNAs’ pools from the diverse tissues. We took
advantage of a qRT-PCR strategy, as it is the most sensitive
method to ascertain gene expression levels. It offers a substantially
higher sensitivity than other conventional methodologies previ-
ously used for HFE transcripts quantification, as southern blot of
RT-PCR products [19], RT-PCR [20] and northern blot [21,22].
As we used pools of RNAs from several healthy individuals, results
represent an average of HFE expression in each tissue, and do not
reflect inter- or intra- individual variability. Using this approach,
we observed that total HFE mRNA expression varies among
tissues. Apart from the gonads, we found that the liver has the
highest total HFE expression. On the contrary, duodenum shows
the lowest HFE expression of the tissues tested. Curiously, the
liver, besides presenting a high level of total HFE mRNA, has the
lowest amount of the studied HFE alternative transcripts. We can
hypothesize that in the liver, wild type (full length) HFE is playing
an important role in iron metabolism. On the contrary,
Figure 4. Cellular localization of HFE splice variants by immunofluorescence analysis. HepG2 cells were transfected with 2 mgo f
pEGFP_HFE_full length, pEGFP_HFE_C282Y, pEGFP_HFE_skip2 and pEGFP_HFE_ivs4 constructs. Twenty-four hours later, cells were submitted to an
immunofluorescence assay. HFE protein variants distribution was compared with the location for (A) beta2-microglobulin (rabbit anti-b2M polyclonal
antibody), (B) transferrin receptor 1 (mouse anti-human TfR1 monoclonal antibody) and (C) endoplasmic reticulum (rabbit anti-calnexin polyclonal
antibody). Images were acquired using a 488-nm laser for GFP (green) and a 532-nm laser for the previously described antibodies (red). Nuclei were
stained with DAPI (blue). Bars represent 10 mm.
doi:10.1371/journal.pone.0017542.g004
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presents a relative high level of the studied alternative transcripts
(approximately 45% of the total). One may speculate that these
alternative transcripts may have a significant function in this tissue.
Having in mind the two models of HFE possible action, the crypt
model [25] and the hepcidin regulation model [13,14,26], we
attempted to further understand the different tissue-level of HFE
transcripts by studying the cellular localization of the overex-
pressed corresponding proteins.
Concerning the HFE exon 2 skipping transcript, which was
already described in hepatic, colon and ovary cell lines [20,22],
here we demonstrate its presence at different levels in several
human tissues. Regarding its corresponding protein, the extracel-
lular a1 domain encoded by exon 2 is lacking, and therefore it is
unable to bind to TfR1 [27]. Our immunofluorescence and
immunoprecipitation results, besides confirming that HFE_skip2 is
not associated with TfR1, also revealed no interaction with the
b2M chaperone and consequent ER retention. It is possible to
conclude that this variant apparently does not have any cellular
function, being probably degraded by the cell proteolytic system.
The other alternative transcript selected to be further
characterized is the one resulting from the intron 4 inclusion. It
presents a tissue-specific regulation, since a relatively more
abundant level of it is found in the testis and in the duodenum
than in other tissues. On the other hand, the lowest level is found
in the liver. Accordingly, a previous study also found different
levels of this transcript in duodenal and liver biopsies of control
and iron overload patients [19].
Analysing the sequence of the intron 4 inclusion transcript we
can observe the presence of a stop codon (TGA) in the open
reading frame, six nucleotides from the exon 4 boundary.
Therefore, this alternative transcript would be expected to be
degraded by the nonsense-mediated mRNA decay mechanism
(NMD), which is a post-transcriptional surveillance mechanism
responsible for the rapid degradation of transcripts harbouring a
premature stop codon. In this way, NMD limits the production of
C-terminally truncated polypeptides and protects the cell from
their possible deleterious dominant-negative or gain-of-function
effects [28]. Nevertheless, this alternative HFE transcript is easily
detected by PCR approaches, thus it may escape NMD or be only
Figure 5. Immunoprecipitation assays of transfected HFE splice variants. HepG2 cells were transfected with pEGFP_HFE_full length,
pEGFP_HFE_C282Y, pEGFP_HFE_skip2 or pEGFP_HFE_ivs4 constructs. (A) Protein expression in HepG2 transfectants prior to immunoprecipitation.
(B) Cell lysates and (C) cell media were subjected to immunoprecipitation using a mouse anti-GFP monoclonal antibody and G-agarose beads. Blots
were incubated with anti-TfR1, -GFP and -b2M antibodies for protein detection. The predicted molecular mass of the proteins is indicated in kDa.
doi:10.1371/journal.pone.0017542.g005
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MHC class I gene, the HLA-G gene, where a similar alternative
transcript is generated (also including a premature stop codon in a
similar position) giving rise to a soluble protein with a recognized
biological function [18]. In fact, it is known that as a consequence of
the alternative splicing mechanism, soluble protein isoforms can be
originated, assuming in some cases, an important regulatory role in
physiological processes. Actually, some years ago, an alternatively
spliced HFE transcript due to the intron 4 inclusion was described
[19]. It was detected at a relatively high level in duodenum biopsies
of normal individuals or with secondary iron overload. On the
contrary, absence or low presence was observed in duodenal
biopsies of HH-C282Y patients. Although not studied at protein
level, it was suggested that the corresponding soluble peptide might
regulate cellular iron transport. Here, we positively showfor the first
time, a soluble HFE protein isoform lacking the transmembrane
domainand the cytoplasmic tail, due to the in frame premature stop
codon present at intron 4 (Figure 2). Since it has an intact a3
domain (encoded by exon 4), it can bind its chaperone b2M, be
correctly folded, conducted to the cell surface and secreted to the
cell medium (Figure 5 and Figure 6). Furthermore, the sHFE
isoform secretion was verified to occur (in addition to HepG2 cell
line) in other diverse types of transfected cell lines (HuH7, HeLa,
HEK293 and CaCo-2), which suggests that it is a widespread event.
Altogether, our results show that HFE gene post-transcriptional
regulation is clearly affected by a tissue-dependent alternative
splicing mechanism. By the approach performed, the alternative
transcripts analysed revealed a distinct level of expression amongst
tissues. However, it would be important to assess their interindi-
vidual variability for each tissue. Consequently, it would be
possible to establish the actual degree of variation between tissues
or organs and thus hypothesize about the physiological importance
of the HFE alternative transcripts.
Regarding the results obtained for the sHFE protein variant,
although its function still requires further investigation, we propose
that this variant may play a role in systemic iron metabolism
regulation. For instance, the sHFE produced in several tissues may
be secreted into the bloodstream and thus bind to cell surface
expressed transferrin receptors (TfR1 or TfR2). Therefore, it could
act as an agonist or an antagonist of the wild type HFE on
hepcidin expression activation in the liver, by controlling the
dietary iron absorption in the duodenum (modulating the
expression of iron-related transporters) or by exerting a role on
iron recycling by macrophages. The function of the sHFE secreted
by duodenum may not be crucial for the systemic iron homeostasis
under iron steady state conditions, as already shown for the full
length HFE [29]. However, it cannot be disregarded a putative
sHFE response to iron imbalance conditions. Therefore, it will be
important to investigate if sHFE serum levels vary with changes in
body iron stores, such as in iron overload disorders (such as HH)
or in iron deficiency conditions. If so, we can also hypothesise that
a sHFE isoform might be developed as an useful therapeutic agent
in the treatment of iron-related disorders.
Materials and Methods
First strand cDNA synthesis and Polymerase Chain
Reaction
First strand cDNA synthesis was performed using 3 mg of total
RNA from each RNA pool of eight human tissues (BD Clontech
or Ambion) and HepG2 cell line (DSMZ ACC 180, Germany), an
equivalent mixture of random primers and oligo(dT)12–18 and the
SuperScriptH II Reverse Transcriptase (RT; Invitrogen), accord-
ing to the manufacturer’s instructions. Using RNAs from different
vendors did not introduce variability in quantification experi-
ments, since ovary RNAs from Clontech and Ambion were
simultaneously tested and similar results were obtained. A
polymerase chain reaction (PCR) covering the entire HFE coding
region was performed to the synthesized cDNAs using primers #1
and #2 (Table 1). A specific PCR to amplify the region between
HFE’s exon 4 to 5 was done using primers #3 and #4.
All products obtained in both PCRs were cloned into the
pCRH-TOPO-XLH vector (Invitrogen), sequenced with BigDye
terminator v1.1 sequencing standard kit using the ABI Prism 3100
automatic sequencer (Applied Biosystems).
Quantitative real-time PCR
The quantification of the alternatively spliced HFE transcripts
was conducted using real-time PCR performed on an ABI Prism
7000 Sequence Detection System. Primers were designed to
amplify specific amplicons for the total HFE (exon 6 – primers #5
and #6), for the exon 2 skipping (exon 1–3 boundary, primers #1
and #7) and for the inclusion of intron 4 (intron 4 - exon 5
boundary, primers #8 and #9) using the ABI Primer Express
software (Applied Biosystems).
Synthesis of cDNA from each tissue was carried out as before.
Each cDNA sample was diluted 5-fold and 5 mL added to 5 mmol
primers and SYBR Green Master Mix (Applied Biosystems). The
cycling parameters were: 10 min at 95uC, followed by 40 cycles of
15 sec at 95uC and 1 min at 65uC. Quantification of gene
expression was performed by the absolute standard curve method.
Plasmid constructs
The cloning of HFE cDNA into the pEGFP-N1 (Clontech) took
advantage of the previously obtained RT-PCR products cloned
into pCRH-TOPO-XL vector. A construct already containing the
total HFE cDNA was used to amplify the entire HFE coding
Figure 6. sHFE cell secretion inhibition. HepG2 cells were
transfected with pEGFP_HFE_full length or pEGFP_HFE_ivs4 constructs
along with Exo I (500 nM) incubation. (A) Cell lysates and (B) cell media
were subjected to immunoprecipitation using a mouse anti-GFP
monoclonal antibody and G-agarose beads. Blots were incubated with
anti-GFP and -b2M antibodies for protein detection. The predicted
molecular mass of the proteins is indicated in kDa.
doi:10.1371/journal.pone.0017542.g006
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BamHI linkers next to the translation start and stop codons (that
was modified in order to allow fusion to GFP open reading frame),
respectively. Both pEGFP-N1 vector and PCR product were
digested with the KpnI and BamHI endonucleases to clone the full
length HFE cDNA fused to GFP (pEGFP_HFE_full length). The
same method was performed to create pEGFP_HFE_skip2
construct, to mimic the exon 2 skipping transcript. To clone the
C282Y mutant control, the pEGFP_HFE_full length was
amplified using mutagenic primers #12 and #13, along with
QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene). In
order to clone the splice variant in which the intron 4 is included,
an antisense primer containing a BamHI linker (primer #14) along
with primer #10 were used to amplify this exon 1 - intron 4
fragment using cDNA from small intestine as a template for the
PCR. Once more, the KpnI and BamHI endonucleases were used
to create the pEGFP_HFE_ivs4 construct. Final sequence analysis
was performed to confirm that all constructs contained the correct
sequence.
Cell culture and transient transfections
HepG2 cells (a human cell line with hepatocyte characteristics),
commercially obtained (DSMZ, ACC 180, Germany) were
maintained in RPMI 1640 medium supplemented with 10%
(v/v) fetal bovine serum in a 37uC/5% CO2 atmosphere. For
transient transfections, cells were seeded in 35 mm plates at a
confluence of 5610
5 or 8610
5 cells per well, for immunofluo-
rescence or immunoprecipitation assays, respectively. Twenty-
four hours after seeding, 2 mg of the pEGFP_HFE constructs
were used together with Lipofectamine 2000 Transfection
Reagent (Invitrogen) or Lipofectamine
TM LTX and PLUS
TM
Reagents (Invitrogen), for immunofluorescence and immunopre-
cipitation assays, respectively. Transfections were performed
following the manufacturer’s instructions. When required, cells
were incubated with Exo I (500 nM) immediately after
transfection. For immunoprecipitation and western blot analyses,
cells and supernatant were harvested 48 hours post-transfection,
whereas for immunofluorescence assays, cells were analyzed
24 hours after transfection.
Immunofluorescence assays
Twenty-four hours after transfection, cells were washed in PBS,
fixed in methanol at 220uC and then washed again. Subsequently,
cells were permeabilized and blocked simultaneously in a PBS
solution containing FBS 10% and Triton X-100 0.5% for 30 min
at room temperature. Incubation with the primary antibodies
[rabbit anti- b2M (Abcam) at 1:200 dilution; mouse anti-TfR1
(Zymed) at 1:100 dilution or rabbit anti-calnexin (SantaCruz
Biotechnology) at 1:50 dilution] was performed for one hour at
room temperature. Afterwards, another incubation was made
using Cy3-conjugated secondary antibodies, anti-mouse or anti-
rabbit (Jackson Immunoresearch Laboratories), both at 1:100
dilution. Nuclei were stained with 10 mg/mL DAPI (Sigma).
Coverslips were then mounted in VectaShield (Vector Laborato-
ries) and sealed. Images were acquired with the 405-nm, 488-nm
and 532-nm laser lines using a Leica DMI 4000B confocal
microscope and processed with Leica Analysis Software.
Immunoprecipitation assays
Forty-eight hours after transfection, both cell media (<2 mL)
and platted cells were harvested. Firstly, cell media were
centrifuged 5 min at 2000 rpm. To their supernatant and cells,
150 mL of lysis buffer [50 mM Tris-HCl at pH 7.5, 1% (v/v) NP-
40, 100 mM NaCl, 10% (v/v) glycerol, 10 mM MgCl2, and a
protease inhibitor cocktail (Sigma)] was added on ice. The media
and cell lysates were cleared by centrifugation and an aliquot of
20 mL (Pre-IP) transferred to 26 Laemmli buffer. To the
remaining supernatant, 5 mL of mouse GFP monoclonal antibody
(Roche) was added. After one hour of incubation at 4uC, 60 mLo f
G-agarose beads slurry (1:1 in lysis buffer) was added and
incubated overnight. Beads were spun down and a 20 mL aliquot
of the supernatant (Post-IP) was added to 26 Laemmli buffer.
Beads were washed and protein resuspended in 26 Laemmli
buffer. These lysates, together with pre- and post-IP aliquots were
analyzed by western blot.
Western blot analysis
Proteins from cell lysates or from cell culture supernatants were
resolved in a 12% SDS-PAGE and transferred to PVDF
membranes (Bio-Rad), which were blocked using a 15% (m/v)
TBST-Milk solution. Membranes were probed using mouse anti-
GFP (Abcam) at 1:10000 dilution, rabbit anti- b2M (Abcam) at
1:500 dilution or mouse anti-TfR1 (Zymed) at 1:500 dilution. For
pre-IP lysates, a mouse anti-PCNA antibody (Calbiochem) was
used as a loading control. Detection was carried out using
secondary peroxidase-conjugated anti-mouse IgG (Bio-Rad) at
1:4000 dilution or anti-rabbit IgG (Bio-Rad) at 1:3000 dilution
antibodies, followed by chemiluminescence assays.
Supporting Information
Figure S1 Expression of HFE exon 2 and exon 3 skipping
splice transcripts in several human tissues and HepG2
cell line. (A) A specific RT-PCR to amplify the region between
HFE exons 1 to 3 using total RNA from eight tissues and HepG2
cell line was performed to evaluate the presence of exon 2
skipping. A schematic representation of the HFE gene exons 1 to 3
is presented on the left. The position of the primers (#S1 and
#S2) used in the PCR and schematic representations of the
identified alternative splicing forms are revealed. (B) A specific
RT-PCR to amplify the region between HFE exons 2 to 4 using
total RNA from eight tissues and HepG2 cell line was performed
to evaluate the presence of exon 3 skipping. A schematic
representation of the HFE gene exons 2 to 4 is presented on the
left. The position of the primers (#S3 and #S4) used in the PCR
and schematic representations of the identified alternative splicing
forms are revealed. Correspondence between these splicing forms
and the PCR amplification products is shown, along with their
length in bp. The asterisks (*) identify bands corresponding to
PCR artefacts as a result from DNA hybrid chains.
(TIF)
Figure S2 Control PCR for genomic DNA contamination
of RNA samples. A PCR to amplify the region between HFE
exon 4 to 5 using cDNA from liver and HepG2 (first two lanes) or
total RNA from eight tissues was performed to evaluate the
possible genomic DNA contamination of the RNA samples.
Splicing forms and the corresponding PCR amplification products
are shown.
(TIF)
Figure S3 Immunoprecipitation assays of transfected
HFE splice variants. CaCo-2 (above) and HeLa (below) cells
were transfected with pEGFP_HFE_full length, pEGFP_
HFE_C282Y, pEGFP_HFE_skip2 or pEGFP_HFE_ivs4 con-
structs. Cell lysates and cell media were subjected to immunopre-
cipitation using a mouse anti-GFP monoclonal antibody and G-
agarose beads. Blots were incubated with anti-GFP and -b2M
Alternative Splicing in HFE
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17542antibodies for protein detection. The predicted molecular mass of
the proteins is indicated in kDa.
(TIF)
Table S1 Supplementary DNA oligonucleotides used in the
current work.
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